Targeted drug delivery strategies for precision medicines.

Targeted drug delivery strategies for precision medicines.
复制标题

DOI:
10.1038/s41578-020-00269-6
复制
发表时间:
2021-04
期刊:
Nature reviews. Materials
影响因子:
--
通讯作者:
Heller DA
Heller DA
中科院分区:
其他
文献类型:
--
作者:
Manzari MT;Shamay Y;Kiguchi H;Rosen N;Scaltriti M;Heller DA

文献摘要

参考文献

被引文献

相似文献

精准医学领域的进步已经改变了癌症治疗的格局。精准医疗是由分子分析、基因组分析和优化药物设计等技术推动的,这些技术可以为个体患者量身定制治疗方案。尽管精准药物已经取得了一些临床成功,但许多潜在治疗方法的使用受到药理学问题的阻碍,包括毒性和耐药性。药物传递材料和方法现在已经发展到可以调节药物的药理学参数而不影响对分子靶点的预期效果的程度。具体来说,它们可以调节药物的药代动力学、稳定性、吸收以及对肿瘤和健康组织的暴露,并促进协同药物组合的施用。这篇综述强调了精确治疗和药物递送的最新进展,并确定了提高癌症药物治疗指数的策略机会,从而改善临床结果。
Progress in the field of precision medicine has changed the landscape of cancer therapy. Precision medicine is propelled by technologies that enable molecular profiling, genomic analysis, and optimized drug design to tailor treatments for individual patients. Although precision medicines have resulted in some clinical successes, the use of many potential therapeutics has been hindered by pharmacological issues, including toxicities and drug resistance. Drug delivery materials and approaches have now advanced to a point where they can enable the modulation of a drug’s pharmacological parameters without compromising the desired effect on molecular targets. Specifically, they can modulate a drug’s pharmacokinetics, stability, absorption, and exposure to tumours and healthy tissues, and facilitate the administration of synergistic drug combinations. This Review highlights recent progress in precision therapeutics and drug delivery, and identifies opportunities for strategies to improve the therapeutic index of cancer drugs, and consequently, clinical outcomes.
DOI: 10.1038/srep36650
发表时间: 2016-11-11
期刊: Scientific reports
影响因子: 4.6
作者:
Ali AA;Hsu FT;Hsieh CL;Shiau CY;Chiang CH;Wei ZH;Chen CY;Huang HS
通讯作者: Huang HS
DOI: 10.1016/j.colsurfb.2014.08.021
发表时间: 2014-11-01
影响因子: 5.8
作者:
Anh Thu Ngoc Lam;Yoon, Jinha;Joo, Sang-Woo
通讯作者: Joo, Sang-Woo
DOI: 10.1002/cpt.1211
发表时间: 2019-07
影响因子: 6.7
作者:
Bartelink IH;Jones EF;Shahidi-Latham SK;Lee PRE;Zheng Y;Vicini P;van 't Veer L;Wolf D;Iagaru A;Kroetz DL;Prideaux B;Cilliers C;Thurber GM;Wimana Z;Gebhart G
通讯作者: Gebhart G
DOI: 10.1021/acs.molpharmaceut.5b00704
发表时间: 2016-01-04
影响因子: 4.9
作者:
Alskär LC;Porter CJ;Bergström CA
通讯作者: Bergström CA
DOI: 10.1016/j.ccr.2011.04.008
发表时间: 2011-05-17
期刊: Cancer cell
影响因子: 50.3
作者:
Carver BS;Chapinski C;Wongvipat J;Hieronymus H;Chen Y;Chandarlapaty S;Arora VK;Le C;Koutcher J;Scher H;Scardino PT;Rosen N;Sawyers CL
通讯作者: Sawyers CL